title: Preventive Effects of Aspirin on Cardiovascular Complications in Prostate Cancer Cases after Endocrinotherapy.
abstract: OBJECTIVE
  To explore the preventive effect of aspirin on the cardiovascular complications in prostate cancer after endocrinotherapy.
  
  
  METHODS
  A total of 92 patients with prostate cancer were divided into observation group (n=44) and control group (n=48). The control group was treated with medical castration plus anti-androgenic drugs. Based on the above treatment, the observation group was added aspirin. The follow-up duration was 2 years. The changes of partial prothrombin time (PT), activated partial thromboplastin time (APTT), platelet aggregation rate (PAG), prostate-specific antigen (PSA) and serum testosterone (T) before and after treatment as well as incidence of cardiovascular disease were observed.
  
  
  RESULTS
  The 2-year survival rates of patients without cardiovascular disease in observation group and control group were 95.45% (42/44) and 72.92% (35/48), respectively, and significant difference was presented between two groups by comparison to the survival rates (χ2=8.5453, p=0.0035). There was no statistical significance between two groups as well as before and after treatment regarding PT (p>0.05). After treatment, APTT went down and PAG was gradually on the rise in control group, while PAG down and APTT on the rise increasingly in observation group. Significant differences were presented between two groups as well as before and after treatment (p<0.01). Both PSA and T levels were decreased significantly in two groups after treatment (p<0.01), but there was no statistical significant between two groups (p>0.05).
  
  
  CONCLUSIONS
  Application of endocrinotherapy in prostate cancer can easily lead to occurrence of cardiovascular disease, but cardiovascular complications can be prevented by aspirin, without affecting the effect of endocrinotherapy.
authors.affiliation: Intensive Care Unit, Zhumadian Central Hospital, Zhumadian, Henan, China E-mail : SYHICU120@163.com.
authors.forename: Xiao-Xia
authors.initials: XX
authors.lastname: Li
authors.forename: Yong-Gang
authors.initials: YG
authors.lastname: Zhang
authors.forename: Dong
authors.initials: D
authors.lastname: Wang
authors.forename: Yun-Fang
authors.initials: YF
authors.lastname: Chen
authors.forename: Yan-Hua
authors.initials: YH
authors.lastname: Shan
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000009:adverse effects*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D001241:Aspirin / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000139:chemically induced / Q000453:epidemiology / Q000401:mortality / Q000517:prevention & control*; D016022:Case-Control Studies; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000150:complications* / Q000188:drug therapy / Q000401:mortality; D015996:Survival Rate
chemical_list: D000726:Androgen Antagonists; D000894:Anti-Inflammatory Agents, Non-Steroidal; D001241:Aspirin